title: ACCE, pharmacogenomics, and stopping clinical trials: time to extend the CONSORT statement?
authors.affiliation: Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, 740 Dr. Penfield, Montreal, QC, Canada. vural.ozdemir@mcgill.ca
authors.forename: Vural
authors.initials: V
authors.lastname: Ozdemir
authors.forename: Yann
authors.initials: Y
authors.lastname: Joly
authors.forename: Bartha M
authors.initials: BM
authors.lastname: Knoppers
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards*; D057239:Early Termination of Clinical Trials; D005820:Genetic Testing / Q000941:ethics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D006801:Humans; D010597:Pharmacogenetics; D011634:Public Health; D011643:Publishing / Q000592:standards / Q000639:trends; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards; D015203:Reproducibility of Results; D016896:Treatment Outcome